Therapeutic Potential of Pigment Epithelium-derived Factor in Cancer

Author(s): Sho-ichi Yamagishi*, Yoshinori Koga, Ami Sotokawauchi, Naoki Hashizume, Suguru Fukahori, Takanori Matsui, Minoru Yagi.

Journal Name: Current Pharmaceutical Design

Volume 25 , Issue 3 , 2019


Abstract:

Pigment epithelium-derived factor (PEDF) is one of the serine protease inhibitors with multifunctional properties, which is produced by various types of organs and tissues. There is an accumulating body of evidence that PEDF plays an important role in the maintenance of tissue homeostasis. Indeed, PEDF not only works as an endogenous inhibitor of angiogenesis, but also suppresses oxidative stress, inflammatory and thrombotic reactions in cell culture systems, animal models, and humans. Furthermore, we, along with others, have found that PEDF inhibits proliferation of, and induces apoptotic cell death in, numerous kinds of tumors. In addition, circulating as well as tumor expression levels of PEDF have been inversely associated with tumor growth and metastasis. These observations suggest that supplementation of PEDF proteins and/or enhancement of endogenous PEDF expression could be a novel therapeutic strategy for the treatment of cancer. Therefore, in this paper, we review the effects of PEDF on diverse types of cancer, and discuss its therapeutic perspectives.

Keywords: Angiogenesis, apoptosis, cancer, inflammation, PEDF, tissue homeostasis.

[1]
Tombran-Tink J, Chader GG, Johnson LV. PEDF: A pigment epithelium-derived factor with potent neuronal differentiative activity. Exp Eye Res 1991; 53(3): 411-4.
[2]
Steele FR, Chader GJ, Johnson LV, Tombran-Tink J. Pigment epithelium-derived factor: neurotrophic activity and identification as a member of the serine protease inhibitor gene family. Proc Natl Acad Sci USA 1993; 90(4): 1526-30.
[3]
Tombran-Tink J, Barnstable CJ. PEDF: A multifaceted neurotrophic factor. Nat Rev Neurosci 2003; 4(8): 628-36.
[4]
Famulla S, Lamers D, Hartwig S, et al. Pigment epithelium-derived factor (PEDF) is one of the most abundant proteins secreted by human adipocytes and induces insulin resistance and inflammatory signaling in muscle and fat cells. Int J Obes 2011; 35(6): 762-72.
[5]
Yamagishi S, Adachi H, Abe A, et al. Elevated serum levels of pigment epithelium-derived factor in the metabolic syndrome. J Clin Endocrinol Metab 2006; 91(6): 2447-50.
[6]
Fukami K, Yamagishi SI, Okuda S. Development of enzyme-linked immunosorbent assay system for PEDF and its clinical utility. Curr Mol Med 2010; 10(3): 317-20.
[7]
Nakamura K, Yamagishi S, Adachi H, Kurita-Nakamura Y, Matsui T, Inoue H. Serum levels of pigment epithelium-derived factor (PEDF) are positively associated with visceral adiposity in Japanese patients with type 2 diabetes. Diabetes Metab Res Rev 2009; 25(1): 52-6.
[8]
Yamagishi S, Matsui T, Adachi H, Takeuchi M. Positive association of circulating levels of advanced glycation end products (AGEs) with pigment epithelium-derived factor (PEDF) in a general population. Pharmacol Res 2010; 61(2): 103-7.
[9]
Nakamura K, Yamagishi S, Yoshida T, et al. Hydrogen peroxide stimulates pigment epithelium-derived factor gene and protein expression in the human hepatocyte cell line OUMS-29. J Int Med Res 2007; 35(3): 427-32.
[10]
Wang JJ, Zhang SX, Lu K, et al. Decreased expression of pigment epithelium-derived factor is involved in the pathogenesis of diabetic nephropathy. Diabetes 2005; 54(1): 243-50.
[11]
Wang JJ, Zhang SX, Mott R, et al. Salutary effect of pigment epithelium-derived factor in diabetic nephropathy: evidence for antifibrogenic activities. Diabetes 2006; 55(6): 1678-85.
[12]
Takenaka K, Yamagishi S, Matsui T, et al. Pigment epithelium-derived factor (PEDF) administration inhibits occlusive thrombus formation in rats: A possible participation of reduced intraplatelet PEDF in thrombosis of acute coronary syndromes. Atherosclerosis 2008; 197(1): 25-33.
[13]
Yabe T, Sanagi T, Yamada H. The neuroprotective role of PEDF: implication for the therapy of neurological disorders. Curr Mol Med 2010; 10(3): 259-66.
[14]
Rychli K, Huber K, Wojta J. Pigment epithelium-derived factor (PEDF) as a therapeutic target in cardiovascular disease. Expert Opin Ther Targets 2009; 13(11): 1295-302.
[15]
Dawson DW, Volpert OV, Gillis P, et al. Pigment epithelium-derived factor: A potent inhibitor of angiogenesis. Science 1999; 285(5425): 245-8.
[16]
Duh EJ, Yang HS, Suzuma I, et al. Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth. Invest Ophthalmol Vis Sci 2002; 43(3): 821-9.
[17]
Spranger J, Osterhoff M, Reimann M, et al. Loss of the antiangiogenic pigment epithelium-derived factor in patients with angiogenic eye disease. Diabetes 2001; 50(12): 2641-5.
[18]
Yamagishi S, Amano S, Inagaki Y, Okamoto T, Takeuchi M, Inoue H. Pigment epithelium-derived factor inhibits leptin-induced angiogenesis by suppressing vascular endothelial growth factor gene expression through anti-oxidative properties. Microvasc Res 2003; 65(3): 186-90.
[19]
Tombran-Tink J. PEDF in angiogenic eye diseases. Curr Mol Med 2010; 10(3): 267-78.
[20]
Yamagishi S, Inagaki Y, Nakamura K, et al. Pigment epithelium-derived factor inhibits TNF-alpha-induced interleukin-6 expression in endothelial cells by suppressing NADPH oxidase-mediated reactive oxygen species generation. J Mol Cell Cardiol 2004; 37(2): 497-506.
[21]
Farnoodian M, Sorenson CM, Sheibani N. PEDF expression affects the oxidative and inflammatory state of choroidal endothelial cells. Am J Physiol Cell Physiol 2018; 314(4): C456-72.
[22]
Yamagishi S, Nakamura K, Ueda S, Kato S, Imaizumi T. Pigment epithelium-derived factor (PEDF) blocks angiotensin II signaling in endothelial cells via suppression of NADPH oxidase: A novel anti-oxidative mechanism of PEDF. Cell Tissue Res 2005; 320(3): 437-45.
[23]
Yamagishi S, Matsui T, Nakamura K, et al. Pigment-Epithelium-Derived Factor (PEDF) inhibits angiotensin-II-induced Vascular Endothelial Growth Factor (VEGF) expression in MOLT-3 T cells through anti-oxidative properties. Microvasc Res 2006; 71(3): 222-6.
[24]
Zhang SX, Wang JJ, Gao G, Shao C, Mott R, Ma JX. Pigment epithelium-derived factor (PEDF) is an endogenous antiinflammatory factor. FASEB J 2006; 20(2): 323-5.
[25]
Yoshida T, Yamagishi S, Nakamura K, et al. Pigment epithelium-derived factor (PEDF) blocks the interleukin-6 signaling to C-reactive protein expression in Hep3B cells by suppressing Rac-1 activation. Life Sci 2006; 79(21): 1981-7.
[26]
Yamagishi S, Kikuchi S, Nakamura K, et al. Pigment epithelium-derived factor (PEDF) blocks angiotensin II-induced T cell adhesion to endothelial cells by suppressing intercellular adhesion molecule-1. Horm Metab Res 2006; 38(8): 546-8.
[27]
Craword SE, Fitchev P, Veliceasa D, Volpert OV. The many facets of PEDF in drug discovery and disease: A diamond in the rough or split personality disorder? Expert Opin Drug Discov 2013; 8(7): 769-92.
[28]
Yamagishi SI, Matsui T. Pigment Epithelium-Derived Factor: A Novel Therapeutic Target for Cardiometabolic Diseases and Related Complications. Curr Med Chem 2018; 25(13): 1480-500.
[29]
Yoshida Y, Yamagishi S, Matsui T, et al. Protective role of pigment epithelium-derived factor (PEDF) in early phase of experimental diabetic retinopathy. Diabetes Metab Res Rev 2009; 25(7): 678-86.
[30]
Ren K, Jiang T, Chen J, Zhao GJ. PEDF ameliorates macrophage inflammation via NF-κB suppression. Int J Cardiol 2017; 247: 42.
[31]
Yamagishi S, Matsui T, Nakamura K. Atheroprotective properties of Pigment Epithelium-derived Factor (PEDF) in cardiometabolic disorders. Curr Pharm Des 2009; 15(9): 1027-33.
[32]
Wen H, Liu M, Liu Z, et al. PEDF improves atherosclerotic plaque stability by inhibiting macrophage inflammation response. Int J Cardiol 2017; 235: 37-41.
[33]
Yamagishi S, Kikuchi S, Nakamura K, Matsui T, Takeuchi M, Inoue H. Pigment Epithelium-derived Factor (PEDF) blocks angiotensin II-induced T cell proliferation by suppressing autocrine production of interleukin-2. Med Chem 2006; 2(3): 265-9.
[34]
Ueda S, Yamagishi SI, Okuda S. Anti-vasopermeability effects of PEDF in retinal-renal disorders. Curr Mol Med 2010; 10(3): 279-83.
[35]
Jinnouchi Y, Yamagishi S, Matsui T, et al. Administration of Pigment Epithelium-derived Factor (PEDF) inhibits cold injury-induced brain edema in mice. Brain Res 2007; 1167: 92-100.
[36]
Lu P, Zhang YQ, Zhang H, et al. Pigment epithelium-derived factor (PEDF) improves ischemic cardiac functional reserve through decreasing hypoxic cardiomyocyte contractility through PEDF receptor (PEDF-R). J Am Heart Assoc 2016; 5(7): 5.
[37]
Yamagishi SI, Matsui T. Anti-atherothrombogenic properties of PEDF. Curr Mol Med 2010; 10(3): 284-91.
[38]
Yamagishi SI, Matsui T, Kawaguchi T, Sata M. Pathophysiological role of pigment epithelium-derived factor (PEDF) in hepatic disorders. Curr Med Chem 2010; 17(19): 1995-2000.
[39]
Yoshida T, Akiba J, Matsui T, et al. Pigment epithelium-derived factor (PEDF) prevents hepatic fat storage, inflammation, and fibrosis in dietary steatohepatitis of mice. Dig Dis Sci 2017; 62(6): 1527-36.
[40]
He X, Cheng R, Park K, et al. Pigment epithelium-derived factor, a noninhibitory serine protease inhibitor, is renoprotective by inhibiting the Wnt pathway. Kidney Int 2017; 91(3): 642-57.
[41]
Chuderland D, Ben-Ami I, Bar-Joseph H, Shalgi R. Role of pigment epithelium-derived factor in the reproductive system. Reproduction 2014; 148(4): R53-61.
[42]
Nakamura K, Yamagishi S, Matsui T, et al. Pigment epithelium-derived factor inhibits neointimal hyperplasia after vascular injury by blocking NADPH oxidase-mediated reactive oxygen species generation. Am J Pathol 2007; 170(6): 2159-70.
[43]
Yamagishi S, Matsui T, Nakamura K, Imaizumi T. Pigment epithelium-derived factor (PEDF) inhibits angiotensin II-induced smooth muscle cell proliferation through its anti-oxidative properties. Protein Pept Lett 2007; 14(6): 615-7.
[44]
Yamagishi S, Abe R, Jinnouchi Y, Matsui T, Imaizumi T, Inoue H. Pigment epithelium-derived factor inhibits vascular endothelial growth factor-induced vascular hyperpermeability both in vitro and in vivo. J Int Med Res 2007; 35(6): 896-9.
[45]
Polato F, Becerra SP. Pigment epithelium-derived factor, a protective factor for photoreceptors in vivo. Adv Exp Med Biol 2016; 854: 699-706.
[46]
Crowe S, Wu LE, Economou C, et al. Pigment epithelium-derived factor contributes to insulin resistance in obesity. Cell Metab 2009; 10(1): 40-7.
[47]
Borg ML, Andrews ZB, Duh EJ, Zechner R, Meikle PJ, Watt MJ. Pigment epithelium-derived factor regulates lipid metabolism via adipose triglyceride lipase. Diabetes 2011; 60(5): 1458-66.
[48]
Yamagishi S, Matsui T, Nakamura K, Takenaka K. Administration of pigment epithelium-derived factor prolongs bleeding time by suppressing plasminogen activator inhibitor-1 activity and platelet aggregation in rats. Clin Exp Med 2009; 9(1): 73-6.
[49]
Baxter-Holland M, Dass CR. Pigment epithelium-derived factor: A key mediator in bone homeostasis and potential for bone regenerative therapy. J Pharm Pharmacol 2018; 70(9): 1127-38.
[50]
Falk T, Gonzalez RT, Sherman SJ. The yin and yang of VEGF and PEDF: multifaceted neurotrophic factors and their potential in the treatment of Parkinson’s Disease. Int J Mol Sci 2010; 11(8): 2875-900.
[51]
Minkevich NI, Lipkin VM, Kostanyan IA. PEDF - A noninhibitory serpin with neurotrophic activity. Acta Naturae 2010; 2(3): 62-71.
[52]
Matsui T, Nishino Y, Maeda S, Yamagishi S. PEDF-derived peptide inhibits corneal angiogenesis by suppressing VEGF expression. Microvasc Res 2012; 84(1): 105-8.
[53]
Kawaguchi T, Yamagishi SI, Sata M. Structure-function relationships of PEDF. Curr Mol Med 2010; 10(3): 302-11.
[54]
Baba H, Yonemitsu Y, Nakano T, et al. Cytoplasmic expression and extracellular deposition of an antiangiogenic factor, pigment epithelium-derived factor, in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2005; 25(9): 1938-44.
[55]
Yamagishi S, Maeda S, Ueda S, Ishibashi Y, Matsui T. Serum pigment epithelium-derived factor levels are independently associated with decreased number of circulating endothelial progenitor cells in healthy non-smokers. Int J Cardiol 2012; 158(2): 310-2.
[56]
Longeras R, Farjo K, Ihnat M, Ma JX. A PEDF-derived peptide inhibits retinal neovascularization and blocks mobilization of bone marrow-derived endothelial progenitor cells. Exp Diabetes Res 2012; 2012518426
[57]
Ho TC, Yang YC, Chen SL, et al. Pigment epithelium-derived factor induces THP-1 macrophage apoptosis and necrosis by the induction of the peroxisome proliferator-activated receptor gamma. Mol Immunol 2008; 45(4): 898-909.
[58]
Yamagishi S, Matsui T, Nakamura K, Takenaka K. Pigment Epithelium-derived Factor (PEDF) inhibits collagen-induced platelet activation by reducing intraplatelet nitrotyrosine levels. Int J Cardiol 2010; 140(1): 121-2.
[59]
Zamiri P, Masli S, Streilein JW, Taylor AW. Pigment epithelial growth factor suppresses inflammation by modulating macrophage activation. Invest Ophthalmol Vis Sci 2006; 47(9): 3912-8.
[60]
Ueda S, Yamagishi S, Matsui T, Jinnouchi Y, Imaizumi T. Administration of pigment epithelium-derived factor inhibits left ventricular remodeling and improves cardiac function in rats with acute myocardial infarction. Am J Pathol 2011; 178(2): 591-8.
[61]
Monaco C, Andreakos E, Kiriakidis S, Feldmann M, Paleolog E. T-cell-mediated signalling in immune, inflammatory and angiogenic processes: the cascade of events leading to inflammatory diseases. Curr Drug Targets Inflamm Allergy 2004; 3(1): 35-42.
[62]
Kratchmarova I, Kalume DE, Blagoev B, et al. A proteomic approach for identification of secreted proteins during the differentiation of 3T3-L1 preadipocytes to adipocytes. Mol Cell Proteomics 2002; 1(3): 213-22.
[63]
Wang M, Wang JJ, Li J, et al. Pigment epithelium-derived factor suppresses adipogenesis via inhibition of the MAPK/ERK pathway in 3T3-L1 preadipocytes. Am J Physiol Endocrinol Metab 2009; 297(6): E1378-87.
[64]
Sabater M, Moreno-Navarrete JM, Ortega FJ, et al. Circulating pigment epithelium-derived factor levels are associated with insulin resistance and decrease after weight loss. J Clin Endocrinol Metab 2010; 95(10): 4720-8.
[65]
Jenkins A, Zhang SX, Gosmanova A, et al. Increased serum pigment epithelium derived factor levels in Type 2 diabetes patients. Diabetes Res Clin Pract 2008; 82(1): e5-7.
[66]
Yang S, Li Q, Zhong L, et al. Serum pigment epithelium-derived factor is elevated in women with polycystic ovary syndrome and correlates with insulin resistance. J Clin Endocrinol Metab 2011; 96(3): 831-6.
[67]
Chen C, Tso AW, Cheung BM, et al. Plasma concentration of pigment epithelium-derived factor is closely associated with blood pressure and predicts incident hypertension in Chinese: A 10-year prospective study. Clin Endocrinol (Oxf) 2012; 76(4): 506-13.
[68]
Chen C, Tso AW, Law LS, et al. Plasma level of pigment epithelium-derived factor is independently associated with the development of the metabolic syndrome in Chinese men: A 10-year prospective study. J Clin Endocrinol Metab 2010; 95(11): 5074-81.
[69]
Oberbach A, von Bergen M, Blüher S, Lehmann S, Till H. Combined serum proteomic and metabonomic profiling after laparoscopic sleeve gastrectomy in children and adolescents. J Laparoendosc Adv Surg Tech A 2012; 22(2): 184-8.
[70]
Böhm A, Ordelheide AM, Machann J, et al. Common genetic variation in the SERPINF1 locus determines overall adiposity, obesity-related insulin resistance, and circulating leptin levels. PLoS One 2012; 7(3)e34035
[71]
Nakamura K, Yamagishi S, Adachi H, Matsui T, Kurita Y, Imaizumi T. Serum levels of Pigment Epithelium-derived Factor (PEDF) are an independent determinant of insulin resistance in patients with essential hypertension. Int J Cardiol 2010; 143(1): 96-8.
[72]
Nakamura K, Yamagishi S, Adachi H, Matsui T, Kurita Y, Inoue H. Serum level of pigment epithelium derived factor (PEDF) is an independent determinant of resting heart rate in Japanese subjects. Int J Cardiol 2009; 136(2): 245-7.
[73]
Lashbrook BL, Steinle JJ. Beta-adrenergic receptor regulation of pigment epithelial-derived factor expression in rat retina. Auton Neurosci 2005; 121(1-2): 33-9.
[74]
Jenkins AJ, Zhang SX, Rowley KG, et al. Increased serum pigment epithelium-derived factor is associated with microvascular complications, vascular stiffness and inflammation in Type 1 diabetes. Diabet Med 2007; 24(12): 1345-51.
[75]
Chen H, Zheng Z, Li R, et al. Urinary pigment epithelium-derived factor as a marker of diabetic nephropathy. Am J Nephrol 2010; 32(1): 47-56.
[76]
Motomiya Y, Yamagishi S, Adachi H, Abe A. Increased serum concentrations of pigment epithelium-derived factor in patients with end-stage renal disease. Clin Chem 2006; 52(10): 1970-1.
[77]
Fujimura T, Yamagishi S, Ueda S, et al. Administration of Pigment Epithelium-derived Factor (PEDF) reduces proteinuria by suppressing decreased nephrin and increased VEGF expression in the glomeruli of adriamycin-injected rats. Nephrol Dial Transplant 2009; 24(5): 1397-406.
[78]
Notari L, Baladron V, Aroca-Aguilar JD, et al. Identification of a lipase-linked cell membrane receptor for pigment epithelium-derived factor. J Biol Chem 2006; 281(49): 38022-37.
[79]
Chung C, Doll JA, Gattu AK, et al. Anti-angiogenic pigment epithelium-derived factor regulates hepatocyte triglyceride content through adipose triglyceride lipase (ATGL). J Hepatol 2008; 48(3): 471-8.
[80]
Chung C, Shugrue C, Nagar A, et al. Ethanol exposure depletes hepatic pigment epithelium-derived factor, a novel lipid regulator. Gastroenterology 2009; 136(1): 331-340.e2.
[81]
Amano S, Yamagishi S, Inagaki Y, et al. Pigment epithelium-derived factor inhibits oxidative stress-induced apoptosis and dysfunction of cultured retinal pericytes. Microvasc Res 2005; 69(1-2): 45-55.
[82]
Yamagishi S, Nakamura K, Takenaka K, Matsui T, Jinnouchi Y, Imaizumi T. Pigment Epithelium-derived Factor (PEDF) promotes growth of pericytes through autocrine production of platelet-derived growth factor-B. Microvasc Res 2005; 69(3): 128-34.
[83]
Ogata N, Tombran-Tink J, Nishikawa M, et al. Pigment epithelium-derived factor in the vitreous is low in diabetic retinopathy and high in rhegmatogenous retinal detachment. Am J Ophthalmol 2001; 132(3): 378-82.
[84]
Liu H, Ren JG, Cooper WL, Hawkins CE, Cowan MR, Tong PY. Identification of the antivasopermeability effect of pigment epithelium-derived factor and its active site. Proc Natl Acad Sci USA 2004; 101(17): 6605-10.
[85]
Zhang SX, Wang JJ, Gao G, Parke K, Ma JX. Pigment epithelium-derived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF-VEGF receptor 2 binding in diabetic retinopathy. J Mol Endocrinol 2006; 37(1): 1-12.
[86]
Funatsu H, Yamashita H, Nakamura S, et al. Vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor are related to diabetic macular edema. Ophthalmology 2006; 113(2): 294-301.
[87]
Yokoi M, Yamagishi S, Saito A, et al. Positive association of pigment epithelium-derived factor with total antioxidant capacity in the vitreous fluid of patients with proliferative diabetic retinopathy. Br J Ophthalmol 2007; 91(7): 885-7.
[88]
Bernard A, Gao-Li J, Franco CA, Bouceba T, Huet A, Li Z. Laminin receptor involvement in the anti-angiogenic activity of pigment epithelium-derived factor. J Biol Chem 2009; 284(16): 10480-90.
[89]
Arimura T, Miura S, Sugihara M, Iwata A, Yamagishi S, Saku K. Association between plasma levels of pigment epithelium-derived factor and renal dysfunction in patients with coronary artery disease. Cardiol J 2011; 18(5): 515-20.
[90]
Shiga Y, Miura S, Mitsutake R, Yamagishi S, Saku K. Significance of plasma levels of pigment epithelium-derived factor as determined by multidetector row computed tomography in patients with mild chronic kidney disease and/or coronary artery disease. J Int Med Res 2011; 39(3): 880-90.
[91]
Tahara N, Yamagishi S, Tahara A, et al. Serum level of pigment epithelium-derived factor is a marker of atherosclerosis in humans. Atherosclerosis 2011; 219(1): 311-5.
[92]
Tombran-Tink J, Shivaram SM, Chader GJ, Johnson LV, Bok D. Expression, secretion, and age-related downregulation of pigment epithelium-derived factor, a serpin with neurotrophic activity. J Neurosci 1995; 15(7 Pt 1): 4992-5003.
[93]
Palmieri D, Watson JM, Rinehart CA. Age-related expression of PEDF/EPC-1 in human endometrial stromal fibroblasts: implications for interactive senescence. Exp Cell Res 1999; 247(1): 142-7.
[94]
Ogata N, Matsuoka M, Imaizumi M, Arichi M, Matsumura M. Decrease of pigment epithelium-derived factor in aqueous humor with increasing age. Am J Ophthalmol 2004; 137(5): 935-6.
[95]
Francis MK, Appel S, Meyer C, Balin SJ, Balin AK, Cristofalo VJ. Loss of EPC-1/PEDF expression during skin aging in vivo. J Invest Dermatol 2004; 122(5): 1096-105.
[96]
Yamagishi S, Imaizumi T. Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. Curr Pharm Des 2005; 11(18): 2279-99.
[97]
Vlassara H, Bucala R, Striker L. Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 1994; 70(2): 138-51.
[98]
Yamagishi S, Nakamura K, Matsui T, Ueda S, Fukami K, Okuda S. Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: A novel therapeutic strategy for diabetic vascular complications. Expert Opin Investig Drugs 2008; 17(7): 983-96.
[99]
Rahbar S, Figarola JL. Novel inhibitors of advanced glycation endproducts. Arch Biochem Biophys 2003; 419(1): 63-79.
[100]
Yamagishi SI, Matsui T. Therapeutic Potential of DNA-aptamers Raised Against AGE-RAGE Axis in Diabetes-related Complications. Curr Pharm Des 2018; 24(24): 2802-9.
[101]
Bierhaus A, Hofmann MA, Ziegler R, Nawroth PP. AGEs and their interaction with AGE-receptors in vascular disease and diabetes mellitus. I. The AGE concept. Cardiovasc Res 1998; 37(3): 586-600.
[102]
Yan SF, D’Agati V, Schmidt AM, Ramasamy R. Receptor for Advanced Glycation Endproducts (RAGE): A formidable force in the pathogenesis of the cardiovascular complications of diabetes & aging. Curr Mol Med 2007; 7(8): 699-710.
[103]
Yamagishi SI, Matsui T, Ishibashi Y, et al. Phytochemicals Against Advanced Glycation End Products (AGEs) and the Receptor System. Curr Pharm Des 2017; 23(8): 1135-41.
[104]
Schmidt AM, Yan SD, Wautier JL, Stern D. Activation of receptor for advanced glycation end products: A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999; 84(5): 489-97.
[105]
Jandeleit-Dahm K, Cooper ME. The role of AGEs in cardiovascular disease. Curr Pharm Des 2008; 14(10): 979-86.
[106]
Yamagishi S, Matsui T, Nakamura K, et al. Pigment-epithelium-derived factor suppresses expression of receptor for advanced glycation end products in the eye of diabetic rats. Ophthalmic Res 2007; 39(2): 92-7.
[107]
Kang MK, Lee EJ, Kim YH, et al. Chrysin ameliorates malfunction of retinoid visual cycle through blocking activation of AGE-RAGE-ER Stress in Glucose-Stimulated Retinal Pigment Epithelial Cells and Diabetic Eyes 2018. 10.
[108]
Yamagishi S, Nakamura K, Matsui T, et al. Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression. J Biol Chem 2006; 281(29): 20213-20.
[109]
Gao L, Hu Y, Li J. Pigment epithelium‑derived factor protects human glomerular mesangial cells from diabetes via NOXO1‑iNOS suppression. Mol Med Rep 2017; 16(5): 7855-63.
[110]
Yoshida T, Yamagishi S, Nakamura K, et al. Pigment epithelium-derived factor (PEDF) inhibits advanced glycation end product (AGE)-induced C-reactive protein expression in hepatoma cells by suppressing Rac-1 activation. FEBS Lett 2006; 580(11): 2788-96.
[111]
Nenna A, Nappi F, Avtaar Singh SS, et al. Pharmacologic Approaches Against Advanced Glycation End Products (AGEs) in Diabetic Cardiovascular Disease. Res Cardiovasc Med 2015; 4(2)e26949
[112]
Yamagishi S, Matsui T, Nakamura K, Takeuchi M, Imaizumi T. Pigment Epithelium-derived Factor (PEDF) prevents diabetes- or advanced glycation end products (AGE)-elicited retinal leukostasis. Microvasc Res 2006; 72(1-2): 86-90.
[113]
Sheikpranbabu S, Haribalaganesh R, Gurunathan S. Pigment epithelium-derived factor inhibits advanced glycation end-products-induced cytotoxicity in retinal pericytes. Diabetes Metab 2011; 37(6): 505-11.
[114]
Yamagishi SI, Nakamura K, Matsui T, Yoshida T, Takeuchi M, Imaizumi T. Pigment Epithelium-derived Factor (PEDF) blocks advanced glycation end product (AGE)-induced angiogenesis in vitro. Horm Metab Res 2007; 39(3): 233-5.
[115]
Sheikpranbabu S, Haribalaganesh R, Lee KJ, Gurunathan S. Pigment epithelium-derived factor inhibits advanced glycation end products-induced retinal vascular permeability. Biochimie 2010; 92(8): 1040-51.
[116]
Maeda S, Matsui T, Takeuchi M, Yamagishi S. Pigment Epithelium-derived Factor (PEDF) blocks advanced glycation end products (AGEs)-RAGE-induced suppression of adiponectin mRNA level in adipocytes by inhibiting NADPH oxidase-mediated oxidative stress generation. Int J Cardiol 2011; 152(3): 408-10.
[117]
Yamagishi S, Ueda S, Matsui T, et al. Pigment Epithelium-derived Factor (PEDF) prevents advanced glycation end products (AGEs)-elicited endothelial nitric oxide synthase (eNOS) reduction through its anti-oxidative properties. Protein Pept Lett 2007; 14(8): 832-5.
[118]
Cohen MP, Hud E, Wu VY, Shearman CW. Amelioration of diabetes-associated abnormalities in the vitreous fluid by an inhibitor of albumin glycation. Invest Ophthalmol Vis Sci 2008; 49(11): 5089-93.
[119]
Yamagishi S, Matsui T, Takenaka K, Nakamura K, Takeuchi M, Inoue H. Pigment epithelium-derived factor (PEDF) prevents platelet activation and aggregation in diabetic rats by blocking deleterious effects of advanced glycation end products (AGEs). Diabetes Metab Res Rev 2009; 25(3): 266-71.
[120]
Yoshida T, Yamagishi S, Nakamura K, et al. Pigment Epithelium-Derived Factor (PEDF) ameliorates advanced glycation end product (AGE)-induced hepatic insulin resistance in vitro by suppressing Rac-1 activation. Horm Metab Res 2008; 40(9): 620-5.
[121]
Ide Y, Matsui T, Ishibashi Y, Takeuchi M, Yamagishi S. Pigment epithelium-derived factor inhibits advanced glycation end product-elicited mesangial cell damage by blocking NF-kappaB activation. Microvasc Res 2010; 80(2): 227-32.
[122]
Maeda S, Matsui T, Takeuchi M, et al. Pigment Epithelium-derived Factor (PEDF) inhibits proximal tubular cell injury in early diabetic nephropathy by suppressing advanced glycation end products (AGEs)-receptor (RAGE) axis. Pharmacol Res 2011; 63(3): 241-8.
[123]
Inagaki Y, Yamagishi S, Okamoto T, Takeuchi M, Amano S. Pigment epithelium-derived factor prevents advanced glycation end products-induced monocyte chemoattractant protein-1 production in microvascular endothelial cells by suppressing intracellular reactive oxygen species generation. Diabetologia 2003; 46(2): 284-7.
[124]
Yamagishi S, Matsui T, Ueda S, Takeuchi M. Pigment epithelium-derived factor (PEDF) inhibits diabetes- or advanced glycation end product (AGE)-induced platelet CD40 ligand overexpression in rats. Int J Cardiol 2010; 144(2): 283-5.
[125]
Fernandez-Garcia NI, Volpert OV, Jimenez B. Pigment epithelium-derived factor as a multifunctional antitumor factor. J Mol Med (Berl) 2007; 85(1): 15-22.
[126]
Ek ET, Dass CR, Choong PF. PEDF: A potential molecular therapeutic target with multiple anti-cancer activities. Trends Mol Med 2006; 12(10): 497-502.
[127]
Belkacemi L, Zhang SX. Anti-tumor effects of pigment epithelium-derived factor (PEDF): implication for cancer therapy. A mini-review. J Exp Clin Cancer Res 2016; 35: 4.
[128]
Filiz G, Dass CR. Reduction in tumour cell invasion by pigment epithelium-derived factor is mediated by membrane type-1 matrix metalloproteinase downregulation. Pharmazie 2012; 67(12): 1010-4.
[129]
Hoshina D, Abe R, Yamagishi SI, Shimizu H. The role of PEDF in tumor growth and metastasis. Curr Mol Med 2010; 10(3): 292-5.
[130]
Fernandez-Garcia NI, Volpert OV, Jimenez B. Pigment epithelium-derived factor as a multifunctional antitumor factor. J Mol Med (Berl) 2007; 85(1): 15-22.
[131]
Yamagishi S, Taguchi K, Fukami K. DNA-aptamers raised against AGEs as a blocker of various aging-related disorders. Glycoconj J 2016; 33(4): 683-90.
[132]
Sharma AK, Sharma VR, Gupta GK, Ashraf GM, Kamal MA. Advanced Glycation End Products (AGEs), Glutathione and Breast Cancer: Factors, Mechanism and Therapeutic Interventions. Curr Drug Metab 2018.
[133]
Nakamura N, Matsui T, Ishibashi Y, et al. RAGE-aptamer Attenuates the Growth and Liver Metastasis of Malignant Melanoma in Nude Mice. Mol Med 2017; 23: 295-306.
[134]
Rojas A, Araya P, Romero J, et al. Skewed Signaling through the Receptor for Advanced Glycation End-Products Alters the Proinflammatory Profile of Tumor-Associated Macrophages. Cancer Microenviron 2018; 11(2-3): 97-105.
[135]
Kong SY, Takeuchi M, Hyogo H, et al. The Association between Glyceraldehyde-Derived Advanced Glycation End-Products and Colorectal Cancer Risk. Cancer Epidemiol Biomarkers Prev 2015; 24(12): 1855-63.
[136]
Palanissami G, Paul SFD. RAGE and Its Ligands: Molecular Interplay Between Glycation, Inflammation, and Hallmarks of Cancer-a Review. Horm Cancer 2018; 9(5): 295-325.
[137]
Yamagishi S, Matsui T, Fukami K. Role of receptor for advanced glycation end products (RAGE) and its ligands in cancer risk. Rejuvenation Res 2015; 18(1): 48-56.
[138]
Kan H, Yamagishi S, Ojima A, et al. Elevation of serum levels of advanced glycation end products in patients with non-B or non-c hepatocellular carcinoma. J Clin Lab Anal 2015; 29(6): 480-4.
[139]
Ojima A, Matsui T, Maeda S, et al. DNA aptamer raised against advanced glycation end products inhibits melanoma growth in nude mice. Lab Invest 2014; 94(4): 422-9.
[140]
Takino J, Yamagishi S, Takeuchi M. Cancer malignancy is enhanced by glyceraldehyde-derived advanced glycation end-products. J Oncol 2010; 2010739852
[141]
Abe R, Yamagishi S. AGE-RAGE system and carcinogenesis. Curr Pharm Des 2008; 14(10): 940-5.
[142]
Rojas A, Añazco C, González I, Araya P. Extracellular matrix glycation and receptor for advanced glycation end-products activation: A missing piece in the puzzle of the association between diabetes and cancer. Carcinogenesis 2018; 39(4): 515-21.
[143]
Ishibashi Y, Matsui T, Takeuchi M, Yamagishi S. Metformin inhibits advanced glycation end products (AGEs)-induced growth and VEGF expression in MCF-7 breast cancer cells by suppressing AGEs receptor expression via AMP-activated protein kinase. Horm Metab Res 2013; 45(5): 387-90.
[144]
Abe R, Shimizu T, Sugawara H, et al. Regulation of human melanoma growth and metastasis by AGE-AGE receptor interactions. J Invest Dermatol 2004; 122(2): 461-7.
[145]
Bordeleau F, Mason BN, Lollis EM, et al. Matrix stiffening promotes a tumor vasculature phenotype. Proc Natl Acad Sci USA 2017; 114(3): 492-7.
[146]
Yamagishi S, Abe R, Inagaki Y, et al. Minodronate, a newly developed nitrogen-containing bisphosphonate, suppresses melanoma growth and improves survival in nude mice by blocking vascular endothelial growth factor signaling. Am J Pathol 2004; 165(6): 1865-74.
[147]
Doll JA, Stellmach VM, Bouck NP, et al. Pigment epithelium-derived factor regulates the vasculature and mass of the prostate and pancreas. Nat Med 2003; 9(6): 774-80.
[148]
Qingyi Z, Lin Y, Junhong W, et al. Unfavorable prognostic value of human PEDF decreased in high-grade prostatic intraepithelial neoplasia: A differential proteomics approach. Cancer Invest 2009; 27(7): 794-801.
[149]
Byrne JC, Downes MR, O’Donoghue N, et al. 2D-DIGE as a strategy to identify serum markers for the progression of prostate cancer. J Proteome Res 2009; 8(2): 942-57.
[150]
Halin S, Wikström P, Rudolfsson SH, et al. Decreased pigment epithelium-derived factor is associated with metastatic phenotype in human and rat prostate tumors. Cancer Res 2004; 64(16): 5664-71.
[151]
Rivera-Pérez J, Monter-Vera MDR, Barrientos-Alvarado C, Toscano-Garibay JD, Cuesta-Mejías T, Flores-Estrada J. Evaluation of VEGF and PEDF in prostate cancer: A preliminary study in serum and biopsies. Oncol Lett 2018; 15(1): 1072-8.
[152]
Ide H, Yamagishi S, Lu Y, et al. Circulating pigment epithelium-derived factor (PEDF) is associated with pathological grade of prostate cancer. Anticancer Res 2015; 35(3): 1703-8.
[153]
Notari L, Baladron V, Aroca-Aguilar JD, et al. Identification of a lipase-linked cell membrane receptor for pigment epithelium-derived factor. J Biol Chem 2006; 281(49): 38022-37.
[154]
Hirsch J, Johnson CL, Nelius T, Kennedy R. Riese Wd, Filleur S. EDF inhibits IL8 production in prostate cancer cells through PEDF receptor/phospholipase A2 and regulation of NFkB and PPARg. Cytokine 2011; 55: 202-10.
[155]
Matsui T, Ojima A, Higashimoto Y, Taira J, Fukami K, Yamagishi SI. Pigment epithelium-derived factor inhibits caveolin-induced interleukin-8 gene expression and proliferation of human prostate cancer cells. Oncol Lett 2015; 10(4): 2644-8.
[156]
Nelius T, Martinez-Marin D, Hirsch J, et al. Pigment epithelium-derived factor expression prolongs survival and enhances the cytotoxicity of low-dose chemotherapy in castration-refractory prostate cancer. Cell Death Dis 2014; 5e1210
[157]
Gong Q, Qiu S, Li S, et al. Proapoptotic PEDF functional peptides inhibit prostate tumor growth--a mechanistic study. Biochem Pharmacol 2014; 92(3): 425-37.
[158]
Mirochnik Y, Aurora A, Schulze-Hoepfner FT, et al. Short pigment epithelial-derived factor-derived peptide inhibits angiogenesis and tumor growth. Clin Cancer Res 2009; 15(5): 1655-63.
[159]
Filleur S, Volz K, Nelius T, et al. Two functional epitopes of pigment epithelial-derived factor block angiogenesis and induce differentiation in prostate cancer. Cancer Res 2005; 65(12): 5144-52.
[160]
Smith ND, Schulze-Hoepfner FT, Veliceasa D, et al. Pigment epithelium-derived factor and interleukin-6 control prostate neuroendocrine differentiation via feed-forward mechanism. J Urol 2008; 179(6): 2427-34.
[161]
Nardi F, Fitchev P, Franco OE, et al. PEDF regulates plasticity of a novel lipid-MTOC axis in prostate cancer-associated fibroblasts. J Cell Sci 2018; 131(13): 131.
[162]
Martinez-Marin D, Jarvis C, Nelius T, de Riese W, Volpert OV, Filleur S. PEDF increases the tumoricidal activity of macrophages towards prostate cancer cells in vitro. PLoS One 2017; 2.
[163]
Nelius T, Samathanam C, Martinez-Marin D, et al. Positive correlation between PEDF expression levels and macrophage density in the human prostate. Prostate 2013; 73(5): 549-61.
[164]
Halin S, Rudolfsson SH, Doll JA, Crawford SE, Wikström P, Bergh A. Pigment epithelium-derived factor stimulates tumor macrophage recruitment and is downregulated by the prostate tumor microenvironment. Neoplasia 2010; 12(4): 336-45.
[165]
Sennoune SR, Bermudez LE, Lees JC, Hirsch J, Filleur S, Martínez-Zaguilán R. Vacuolar H+-ATPase is down-regulated by the angiogenesis-inhibitory pigment epithelium-derived factor in metastatic prostate cancer cells. Cell Mol Biol 2014; 60(1): 45-52.
[166]
Guan M, Jiang H, Xu C, Xu R, Chen Z, Lu Y. Adenovirus-mediated PEDF expression inhibits prostate cancer cell growth and results in augmented expression of PAI-2. Cancer Biol Ther 2007; 6(3): 419-25.
[167]
Chen X, Li C, He T, et al. Metformin inhibits prostate cancer cell proliferation, migration, and tumor growth through upregulation of PEDF expression. Cancer Biol Ther 2016; 17(5): 507-14.
[168]
Zolochevska O, Shearer J, Ellis J, et al. Human adipose-derived mesenchymal stromal cell pigment epithelium-derived factor cytotherapy modifies genetic and epigenetic profiles of prostate cancer cells. Cytotherapy 2014; 16(3): 346-56.
[169]
Cai J, Parr C, Watkins G, Jiang WG, Boulton M. Decreased pigment epithelium-derived factor expression in human breast cancer progression. Clin Cancer Res 2006; 12(11 Pt 1): 3510-7.
[170]
Phang WM, Tan AA, Gopinath SC, Hashim OH, Kiew LV, Chen Y. Secretion of N- and O-linked Glycoproteins from 4T1 Murine Mammary Carcinoma Cells. Int J Med Sci 2016; 13(5): 330-9.
[171]
Gnerlich JL, Yao KA, Fitchev PS, et al. Peritumoral expression of adipokines and fatty acids in breast cancer. Ann Surg Oncol 2013; 20(Suppl. 3): S731-8.
[172]
Zhou D, Cheng SQ, Ji HF, et al. Evaluation of protein pigment epithelium-derived factor (PEDF) and microvessel density (MVD) as prognostic indicators in breast cancer. J Cancer Res Clin Oncol 2010; 136(11): 1719-27.
[173]
Zhou D, Zhang M, Xu P, et al. Expression of pigment epithelium-derived factor is associated with a good prognosis and is correlated with epithelial-mesenchymal transition-related genes in infiltrating ductal breast carcinoma. Oncol Lett 2016; 11(1): 116-24.
[174]
Hong H, Zhou T, Fang S, et al. Pigment epithelium-derived factor (PEDF) inhibits breast cancer metastasis by down-regulating fibronectin. Breast Cancer Res Treat 2014; 148(1): 61-72.
[175]
Fitzgerald DP, Subramanian P, Deshpande M, et al. Opposing effects of pigment epithelium-derived factor on breast cancer cell versus neuronal survival: implication for brain metastasis and metastasis-induced brain damage. Cancer Res 2012; 72(1): 144-53.
[176]
Jan R, Huang M, Lewis-Wambi J. Loss of pigment epithelium-derived factor: A novel mechanism for the development of endocrine resistance in breast cancer. Breast Cancer Res 2012; 14(6): R146.
[177]
Konson A, Pradeep S, Seger R. Phosphomimetic mutants of pigment epithelium-derived factor with enhanced antiangiogenic activity as potent anticancer agents. Cancer Res 2010; 70(15): 6247-57.
[178]
Koskimaki JE, Rosca EV, Rivera CG, et al. Serpin-derived peptides are antiangiogenic and suppress breast tumor xenograft growth. Transl Oncol 2012; 5(2): 92-7.
[179]
Belkacemi L, Atkins JL, Yang LU, et al. Phosphaplatin anti-tumor effect enhanced by liposomes partly via an up-regulation of PEDF in breast cancer. Anticancer Res 2018; 38(2): 623-46.
[180]
Low HP, Tiwari A, Janjanam J, et al. Screening preeclamptic cord plasma for proteins associated with decreased breast cancer susceptibility. Genomics Proteomics Bioinformatics 2013; 11(6): 335-44.
[181]
Abe R, Shimizu T, Yamagishi S, et al. Overexpression of pigment epithelium-derived factor decreases angiogenesis and inhibits the growth of human malignant melanoma cells in vivo. Am J Pathol 2004; 164(4): 1225-32.
[182]
Dadras SS, Lin RJ, Razavi G, et al. A novel role for microphthalmia-associated transcription factor-regulated pigment epithelium-derived factor during melanoma progression. Am J Pathol 2015; 185(1): 252-65.
[183]
Zhang CF, Xiang LH, Shen J, Zhang Y, Li J, Zheng ZZ. Expression of pigment epithelium-derived factor in human melanocytes and malignant melanoma cells and tissues: Is loss of pigment epithelium-derived factor associated with melanoma? Dermatoendocrinol 2009; 1(2): 108-13.
[184]
Abe R, Fujita Y, Yamagishi S. Angiogenesis and metastasis inhibitors for the treatment of malignant melanoma. Mini Rev Med Chem 2007; 7(6): 649-61.
[185]
Abe R, Fujita Y, Yamagishi S, Shimizu H. Pigment epithelium-derived factor prevents melanoma growth via angiogenesis inhibition. Curr Pharm Des 2008; 14(36): 3802-9.
[186]
Yang LP, Cheng P, Peng XC, et al. Anti-tumor effect of adenovirus-mediated gene transfer of pigment epithelium-derived factor on mouse B16-F10 melanoma. J Exp Clin Cancer Res 2009; 28: 75.
[187]
Yang H, Grossniklaus HE. Constitutive overexpression of pigment epithelium-derived factor inhibition of ocular melanoma growth and metastasis. Invest Ophthalmol Vis Sci 2010; 51(1): 28-34.
[188]
Garcia M, Fernandez-Garcia NI, Rivas V, et al. Inhibition of xenografted human melanoma growth and prevention of metastasis development by dual antiangiogenic/antitumor activities of pigment epithelium-derived factor. Cancer Res 2004; 64(16): 5632-42.
[189]
Chen Q, Cheng P, Song N, et al. Antitumor activity of placenta-derived mesenchymal stem cells producing pigment epithelium-derived factor in a mouse melanoma model. Oncol Lett 2012; 4(3): 413-8.
[190]
Shi HS, Yang LP, Wei W, et al. Systemically administered liposome-encapsulated Ad-PEDF potentiates the anti-cancer effects in mouse lung metastasis melanoma. J Transl Med 2013; 11: 86.
[191]
Orgaz JL, Benguria A, Sanchez-Martinez C, Ladhani O, Volpert OV, Jimenez B. Changes in the gene expression profile of A375 human melanoma cells induced by overexpression of multifunctional pigment epithelium-derived factor. Melanoma Res 2011; 21(4): 285-97.
[192]
Ladhani O, Sánchez-Martinez C, Orgaz JL, Jimenez B, Volpert OV. Pigment epithelium-derived factor blocks tumor extravasation by suppressing amoeboid morphology and mesenchymal proteolysis. Neoplasia 2011; 13(7): 633-42.
[193]
Fernández-Barral A, Orgaz JL, Gomez V, del Peso L, Calzada MJ, Jiménez B. Hypoxia negatively regulates antimetastatic PEDF in melanoma cells by a hypoxia inducible factor-independent, autophagy dependent mechanism. PLoS One 2012; 7(3)e32989
[194]
Yang H, Xu Z, Iuvone PM, Grossniklaus HE. Angiostatin decreases cell migration and vascular endothelium growth factor (VEGF) to pigment epithelium derived factor (PEDF) RNA ratio in vitro and in a murine ocular melanoma model. Mol Vis 2006; 12: 511-7.
[195]
Lattier JM, Yang H, Crawford S, Grossniklaus HE. Host pigment epithelium-derived factor (PEDF) prevents progression of liver metastasis in a mouse model of uveal melanoma. Clin Exp Metastasis 2013; 30(8): 969-76.
[196]
Orgaz JL, Ladhani O, Hoek KS, et al. ‘Loss of pigment epithelium-derived factor enables migration, invasion and metastatic spread of human melanoma’. Oncogene 2009; 28(47): 4147-61.
[197]
Fernández-Barral A, Orgaz JL, Baquero P, et al. Regulatory and functional connection of microphthalmia-associated transcription factor and anti-metastatic pigment epithelium derived factor in melanoma. Neoplasia 2014; 16(6): 529-42.
[198]
Nwani NG, Deguiz ML, Jimenez B, et al. Melanoma Cells Block PEDF Production in Fibroblasts to Induce the Tumor-Promoting Phenotype of Cancer-Associated Fibroblasts. Cancer Res 2016; 76(8): 2265-76.
[199]
Plebanek MP, Angeloni NL, Vinokour E, et al. Pre-metastatic cancer exosomes induce immune surveillance by patrolling monocytes at the metastatic niche. Nat Commun 2017; 8(1): 1319.
[200]
Feng Y, Bao W, Luo Y, et al. Phosphomimetic mutants of pigment epithelium-derived factor with enhanced anti-choroidal melanoma cell activity in vitro and in vivo. Invest Ophthalmol Vis Sci 2012; 53(11): 6793-802.
[201]
Jia L, Waxman DJ. Thrombospondin-1 and pigment epithelium-derived factor enhance responsiveness of KM12 colon tumor to metronomic cyclophosphamide but have disparate effects on tumor metastasis. Cancer Lett 2013; 330(2): 241-9.
[202]
Yi H, Ji D, Zhan T, et al. Prognostic value of pigment epithelium-derived factor for neoadjuvant radiation therapy in patients with locally advanced rectal carcinoma. Int J Oncol 2016; 49(4): 1415-26.
[203]
Mahtabifard A, Merritt RE, Yamada RE, Crystal RG, Korst RJ. In vivo gene transfer of pigment epithelium-derived factor inhibits tumor growth in syngeneic murine models of thoracic malignancies. J Thorac Cardiovasc Surg 2003; 126(1): 28-38.
[204]
Wu QJ, Gong CY, Luo ST, et al. AAV-mediated human PEDF inhibits tumor growth and metastasis in murine colorectal peritoneal carcinomatosis model. BMC Cancer 2012; 12: 129.
[205]
Yang L, Zhang Y, Cheng L, et al. Mesenchymal Stem Cells Engineered to Secrete Pigment Epithelium-Derived Factor Inhibit Tumor Metastasis and the Formation of Malignant Ascites in a Murine Colorectal Peritoneal Carcinomatosis Model. Hum Gene Ther 2016; 27(3): 267-77.
[206]
Cui FY, Song XR, Li ZY, et al. The pigment epithelial-derived factor gene loaded in PLGA nanoparticles for therapy of colon carcinoma. Oncol Rep 2010; 24(3): 661-8.
[207]
Ji D, Li M, Zhan T, et al. Prognostic role of serum AZGP1, PEDF and PRDX2 in colorectal cancer patients. Carcinogenesis 2013; 34(6): 1265-72.
[208]
Wågsäter D, Löfgren S, Zar N, Hugander A, Dimberg J. Pigment epithelium-derived factor expression in colorectal cancer patients. Cancer Invest 2010; 28(8): 872-7.
[209]
Zhang Y, Han J, Yang X, et al. Pigment epithelium-derived factor inhibits angiogenesis and growth of gastric carcinoma by down-regulation of VEGF. Oncol Rep 2011; 26(3): 681-6.
[210]
Seki R, Yamagishi S, Matsui T, et al. Pigment Epithelium-Derived Factor (PEDF) inhibits survival and proliferation of VEGF-exposed multiple myeloma cells through its anti-oxidative properties. Biochem Biophys Res Commun 2013; 431(4): 693-7.
[211]
Matsui T, Higashimoto Y, Yamagishi S. Laminin receptor mediates anti-inflammatory and anti-thrombogenic effects of pigment epithelium-derived factor in myeloma cells. Biochem Biophys Res Commun 2014; 443(3): 847-51.
[212]
Matsumoto K, Ishikawa H, Nishimura D, Hamasaki K, Nakao K, Eguchi K. Antiangiogenic property of pigment epithelium-derived factor in hepatocellular carcinoma. Hepatology 2004; 40(1): 252-9.
[213]
Jeng KS, Sheen IS, Jeng WJ, Su JC. PEDF effectively decreases VEGF to PEDF messenger RNA ratio of the inner edge of rat hepatocellular carcinoma induced by diethyl nitrosamine - an “in vivo” study. Hepatogastroenterology 2012; 59(117): 1484-90.
[214]
Gao Y, Yao A, Zhang W, et al. Human mesenchymal stem cells overexpressing pigment epithelium-derived factor inhibit hepatocellular carcinoma in nude mice. Oncogene 2010; 29(19): 2784-94.
[215]
Wang X, Xiu P, Wang F, et al. P18 peptide, a functional fragment of pigment epithelial-derived factor, inhibits angiogenesis in hepatocellular carcinoma via modulating VEGF/VEGFR2 signalling pathway. Oncol Rep 2017; 38(2): 755-66.
[216]
Lai LJ, Ho TC. Pigment epithelial-derived factor inhibits c-FLIP expression and assists ciglitazone-induced apoptosis in hepatocellular carcinoma. Anticancer Res 2011; 31(4): 1173-80.
[217]
Hou J, Ge C, Cui M, et al. Pigment epithelium-derived factor promotes tumor metastasis through an interaction with laminin receptor in hepatocellular carcinomas. Cell Death Dis 2017; 8(8)e2969
[218]
Kawaguchi T, Yamagishi S, Itou M, et al. Pigment epithelium-derived factor inhibits lysosomal degradation of Bcl-xL and apoptosis in HepG2 cells. Am J Pathol 2010; 176(1): 168-76.
[219]
Hase R, Miyamoto M, Uehara H, et al. Pigment epithelium-derived factor gene therapy inhibits human pancreatic cancer in mice. Clin Cancer Res 2005; 11(24 Pt 1): 8737-44.
[220]
Grippo PJ, Fitchev PS, Bentrem DJ, et al. Concurrent PEDF deficiency and Kras mutation induce invasive pancreatic cancer and adipose-rich stroma in mice. Gut 2012; 61(10): 1454-64.
[221]
Principe DR, DeCant B, Diaz AM, et al. PEDF inhibits pancreatic tumorigenesis by attenuating the fibro-inflammatory reaction. Oncotarget 2016; 7(19): 28218-34.
[222]
Uehara H, Miyamoto M, Kato K, et al. Expression of pigment epithelium-derived factor decreases liver metastasis and correlates with favorable prognosis for patients with ductal pancreatic adenocarcinoma. Cancer Res 2004; 64(10): 3533-7.
[223]
Samkharadze T, Erkan M, Reiser-Erkan C, et al. Pigment epithelium-derived factor associates with neuropathy and fibrosis in pancreatic cancer. Am J Gastroenterol 2011; 106(5): 968-80.
[224]
Gong J, Belinsky G, Sagheer U, Zhang X, Grippo PJ, Chung C. Pigment Epithelium-derived Factor (PEDF) Blocks Wnt3a Protein-induced Autophagy in Pancreatic Intraepithelial Neoplasms. J Biol Chem 2016; 291(42): 22074-85.
[225]
Sánchez-Otero N, Blanco-Prieto S, Vázquez-Iglesias L, et al. Levels of PEDF in pleural effusions from lung adenocarcinoma and benign disease patients. Dis Markers 2013; 34(6): 425-30.
[226]
Rodríguez-Piñeiro AM, Blanco-Prieto S, Sánchez-Otero N, Rodríguez-Berrocal FJ, de la Cadena MP. On the identification of biomarkers for non-small cell lung cancer in serum and pleural effusion. J Proteomics 2010; 73(8): 1511-22.
[227]
Zhang L, Chen J, Ke Y, Mansel RE, Jiang WG. Expression of pigment epithelial derived factor is reduced in non-small cell lung cancer and is linked to clinical outcome. Int J Mol Med 2006; 17(5): 937-44.
[228]
Chen J, Ye L, Zhang L, Jiang WG. The molecular impact of pigment epithelium-derived factor, PEDF, on lung cancer cells and the clinical significance. Int J Oncol 2009; 35(1): 159-66.
[229]
Huang WT, Chong IW, Chen HL, et al. Pigment epithelium-derived factor inhibits lung cancer migration and invasion by upregulating exosomal thrombospondin 1. Cancer Lett 2019; 442: 287-98.
[230]
He SS, Shi HS, Yin T, et al. AAV-mediated gene transfer of human pigment epithelium-derived factor inhibits Lewis lung carcinoma growth in mice. Oncol Rep 2012; 27(4): 1142-8.
[231]
Li L, Yao YC, Fang SH, et al. Pigment Epithelial-derived Factor (PEDF)-triggered lung cancer cell apoptosis relies on p53 protein-driven Fas ligand (Fas-L) up-regulation and Fas protein cell surface translocation. J Biol Chem 2014; 289(44): 30785-99.
[232]
Chen Q, Cheng P, Yin T, et al. Therapeutic potential of bone marrow-derived mesenchymal stem cells producing pigment epithelium-derived factor in lung carcinoma. Int J Mol Med 2012; 30(3): 527-34.
[233]
Xu Z, Dong Y, Peng F, et al. Pigment epithelium-derived factor enhances tumor response to radiation through vasculature normalization in allografted lung cancer in mice. Cancer Gene Ther 2015; 22(4): 181-7.
[234]
He SS, Wu QJ, Gong CY, et al. Enhanced efficacy of combination therapy with adeno‑associated virus-delivered pigment epithelium-derived factor and cisplatin in a mouse model of Lewis lung carcinoma. Mol Med Rep 2014; 9(6): 2069-76.
[235]
Zhang T, Guan M, Xu C, Chen Y, Lu Y. Pigment epithelium-derived factor inhibits glioma cell growth in vitro and in vivo. Life Sci 2007; 81(16): 1256-63.
[236]
Wang Q, Zhang Z, Ding T, Chen Z, Zhang T. Mesenchymal stem cells overexpressing PEDF decrease the angiogenesis of gliomas. Biosci Rep 2013; 33(2)e00019
[237]
Guan M, Yam HF, Su B, et al. Loss of pigment epithelium derived factor expression in glioma progression. J Clin Pathol 2003; 56(4): 277-82.
[238]
Yin J, Park G, Kim TH, et al. Pigment epithelium-derived factor (PEDF) expression induced by EGFRvIII promotes self-renewal and tumor progression of glioma stem cells. PLoS Biol 2015; 13(5)e1002152
[239]
Feng CC, Ding Q, Zhang YF, et al. Pigment epithelium-derived factor expression is down-regulated in bladder tumors and correlates with vascular endothelial growth factor and matrix metalloproteinase-9. Int Urol Nephrol 2011; 43(2): 383-90.
[240]
Feng CC, Wang PH, Ding Q, et al. Expression of pigment epithelium-derived factor and tumor necrosis factor-α is correlated in bladder tumor and is related to tumor angiogenesis. Urol Oncol 2013; 31(2): 241-6.
[241]
Feng C, Guan M, Ding Q, et al. Expression of pigment epithelium-derived factor in bladder tumour is correlated with interleukin-8 yet not with interleukin-1α. J Huazhong Univ Sci Technolog Med Sci 2011; 31(1): 21-5.
[242]
Dong BB, Yan JS, Yan YY, et al. Downregulation of pigment epithelium-derived factor is associated with increased epithelial-mesenchymal transition in bladder cancer. Panminerva Med 2017; 59(1): 9-14.
[243]
Deshpande M, Notari L, Subramanian P, Notario V, Becerra SP. Inhibition of tumor cell surface ATP synthesis by pigment epithelium-derived factor: implications for antitumor activity. Int J Oncol 2012; 41(1): 219-27.
[244]
Jiang H, Bu Q, Zeng M, Xia D, Wu A. MicroRNA-93 promotes bladder cancer proliferation and invasion by targeting PEDF. Urol Oncol 2019; 37(2): 150-7.
[245]
Daubriac J, Pandya UM, Huang KT, et al. Hormonal and growth regulation of epithelial and stromal cells from the normal and malignant endometrium by pigment epithelium-derived factor. Endocrinology 2017; 158(9): 2754-73.
[246]
Guo T, Gu C, Li B. PEDF inhibits growth and invasiveness of endometrial cancer cells in vitro. Panminerva Med 2012; 54(4): 299-304.
[247]
Han J, Guo J. Current evidence and potential mechanisms of therapeutic action of PEDF in cervical cancer treatment. Curr Mol Med 2015; 15(5): 446-55.
[248]
Yang Y, He L, Liu Y, et al. Promising nanocarriers for PEDF gene targeting delivery to cervical cancer cells mediated by the over-expressing FRα. Sci Rep 2016; 6: 32427.
[249]
Yang J, Chen S, Huang X, et al. Growth suppression of cervical carcinoma by pigment epithelium-derived factor via anti-angiogenesis. Cancer Biol Ther 2010; 9(12): 967-74.
[250]
Cheung LW, Au SC, Cheung AN, et al. Pigment epithelium-derived factor is estrogen sensitive and inhibits the growth of human ovarian cancer and ovarian surface epithelial cells. Endocrinology 2006; 147(9): 4179-91.
[251]
Dass CR, Ek ET, Choong PF. PEDF as an emerging therapeutic candidate for osteosarcoma. Curr Cancer Drug Targets 2008; 8(8): 683-90.
[252]
Takenaka K, Yamagishi S, Jinnouchi Y, Nakamura K, Matsui T, Imaizumi T. Pigment epithelium-derived factor (PEDF)-induced apoptosis and inhibition of vascular endothelial growth factor (VEGF) expression in MG63 human osteosarcoma cells. Life Sci 2005; 77(25): 3231-41.
[253]
Ek ET, Dass CR, Contreras KG, Choong PF. Inhibition of orthotopic osteosarcoma growth and metastasis by multitargeted antitumor activities of pigment epithelium-derived factor. Clin Exp Metastasis 2007; 24(2): 93-106.
[254]
Ek ET, Dass CR, Contreras KG, Choong PF. Pigment epithelium-derived factor overexpression inhibits orthotopic osteosarcoma growth, angiogenesis and metastasis. Cancer Gene Ther 2007; 14(7): 616-26.
[255]
Dass CR, Contreras KG, Dunstan DE, Choong PF. Chitosan microparticles encapsulating PEDF plasmid demonstrate efficacy in an orthotopic metastatic model of osteosarcoma. Biomaterials 2007; 28(19): 3026-33.
[256]
Broadhead ML, Dass CR, Choong PF. Systemically administered PEDF against primary and secondary tumours in a clinically relevant osteosarcoma model. Br J Cancer 2011; 105(10): 1503-11.
[257]
Broadhead ML, Lokmic Z, Tan ML, et al. Applying advanced imaging techniques to a murine model of orthotopic osteosarcoma. Front Surg 2015; 2: 36.
[258]
Ek ET, Dass CR, Contreras KG, Choong PF. PEDF-derived synthetic peptides exhibit antitumor activity in an orthotopic model of human osteosarcoma. J Orthop Res 2007; 25(12): 1671-80.
[259]
Jiang Z, Fang Z, Ding Q. Prognostic role of pigment epithelium-derived factor in clear cell renal cell carcinoma. Urol Int 2010; 84(3): 334-40.
[260]
Wang L, Yang G, Zhu X, et al. miR-93-3p inhibition suppresses clear cell renal cell carcinoma proliferation, metastasis and invasion. Oncotarget 2017; 8(47): 82824-34.
[261]
Liu LJ, Yu JJ, Xu XL. MicroRNA-93 inhibits apoptosis and promotes proliferation, invasion and migration of renal cell carcinoma ACHN cells via the TGF-β/Smad signaling pathway by targeting RUNX3. Am J Transl Res 2017; 9(7): 3499-513.


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 25
ISSUE: 3
Year: 2019
Page: [313 - 324]
Pages: 12
DOI: 10.2174/1381612825666190319112106
Price: $65

Article Metrics

PDF: 24
HTML: 7
EPUB: 1

Special-new-year-discount